SCHEMBL6809221

SCHEMBL6809221

CCOc1cc(-c2ccc(C(=O)OC)cc2)nn1CCOc1ccc(-c2ccc(-c3ccccc3)cc2F)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TP53 P04637 2/20 0.39
MDM2 Q00987 2/20 0.39
EGFR P00533 1/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GCGR P47871 1/20 0.38
GIPR P48546 1/20 0.38
PDE4B Q07343 3/20 0.38
NLRP3 Q96P20 1/20 0.37
BCL9 O00512 1/20 0.36
CTNNB1 P35222 1/20 0.36
FAAH O00519 1/20 0.36
PTGS2 P35354 1/20 0.35
ACLY P53396 2/20 0.35
ALDH1A3 P47895 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6809196 0.93 TP53 (0.46) TP53MDM2EGFRALDH1A1MAPT
SCHEMBL6600937 0.92 TP53 (0.41) MEN1KMT2ATP53MDM2ALDH1A1
SCHEMBL6804100 0.91 NLRP3 (0.39) MEN1KMT2ATP53MDM2ALDH1A1
SCHEMBL6607403 0.89 NLRP3 (0.43) MEN1KMT2ATP53ALDH1A1MAPT
SCHEMBL6805285 0.86 TP53 (0.49) KMT2ATP53MDM2ALDH1A1MAPT
SCHEMBL6601993 0.86 MEN1 (0.41) MEN1KMT2ATP53MDM2ALDH1A1
SCHEMBL6800862 0.85 NLRP3 (0.43) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL6805484 0.85 TP53 (0.45) TP53MDM2GCGRGIPR
SCHEMBL6804785 0.84 TP53 (0.38) KMT2ATP53MDM2ALDH1A1MAPT
SCHEMBL6607205 0.84 NLRP3 (0.40) MEN1KMT2ATP53MDM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 MEN1 2036/4885KMT2A 2911/4885TP53 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.